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Patrick Waters,1 Sarosh R. Irani1 and the Faciobrachial Dystonic Seizures Study Group†
*These authors contributed equally to this work.
†Appendix 1.
Faciobrachial dystonic seizures and limbic encephalitis closely associate with antibodies to leucine-rich glioma-inactivated 1 (LGI1).
Here, we describe 103 consecutive patients with faciobrachial dystonic seizures and LGI1 antibodies to understand clinical,
therapeutic and serological differences between those with and without cognitive impairment, and to determine whether cessation
of faciobrachial dystonic seizures can prevent cognitive impairment. The 22/103 patients without cognitive impairment typically
had normal brain MRI, EEGs and serum sodium levels (P5 0.0001). Overall, cessation of faciobrachial dystonic seizures with
antiepileptic drugs alone occurred in only 9/89 (10%) patients. By contrast, 51% showed cessation of faciobrachial dystonic
seizures 30 days after addition of immunotherapy (P5 0.0001), with earlier cessation in cognitively normal patients (P = 0.038).
Indeed, expedited immunotherapy (P = 0.031) and normal cognition (P = 0.0014) also predicted reduced disability at 24 months.
Furthermore, of 80 patients with faciobrachial dystonic seizures as their initial feature, 56% developed cognitive impairment after
90 days of active faciobrachial dystonic seizures. Whereas only one patient developed cognitive impairment after cessation of
faciobrachial dystonic seizures (P5 0.0001). All patients had IgG4-LGI1 antibodies, but those with cognitive impairment had
higher proportions of complement-fixing IgG1 antibodies (P = 0.03). Both subclasses caused LGI1-ADAM22 complex internaliza-
tion, a potential non-inflammatory epileptogenic mechanism. In summary, faciobrachial dystonic seizures show striking time-sen-
sitive responses to immunotherapy, and their cessation can prevent the development of cognitive impairment.
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Introduction
Autoantibodies to leucine-rich glioma-inactivated 1 (LGI1)
are associated with a limbic encephalitis. This presents with
the subacute onset of frequent seizures and cognitive impair-
ment, characterized by amnesia, confusion and executive
dysfunction, often with hyponatraemia and medial temporal
lobe high-signal on T2-weighted MRI (Thieben et al., 2004;
Vincent et al., 2004; Irani et al., 2010; Lai et al., 2010).
Patients improve with immunotherapies, but frequently have
significant residual cognitive deficits (Butler et al., 2014;
Arin˜o et al., 2016; Finke et al., 2017).
In addition, LGI1 antibodies are associated with a highly
specific focal seizure semiology termed faciobrachial dystonic
seizures (FBDS) (Irani et al., 2008, 2011, 2013; Flanagan
et al., 2015). Recognition of this characteristic semiology
permits an accurate clinical diagnosis without ancillary test-
ing (Sen et al., 2014). Experiences from several small studies
have suggested that FBDS appear preferentially responsive to
immunotherapy over antiepileptic drugs (AEDs) (Irani et al.,
2008, 2011, 2013; Flanagan et al., 2015; Navarro et al.,
2016; van Sonderen et al., 2016). However, these studies
provided limited quantification of treatment timings and
minimal follow-up. Moreover, some untreated patients
demonstrated improvements (Szots et al., 2014). Therefore,
FBDS represent an increasingly recognized condition about
which the impacts of treatment type and delay have received
little attention, even in the largest dedicated series of 29
patients (Irani et al., 2011). Furthermore, there has been
no systematic characterization of patients with FBDS with-
out cognitive impairment. This may be especially informative
as FBDS often predate the onset of cognitive impairment
(Irani et al., 2011, 2013; van Sonderen et al., 2016). Here,
we present a series of 103 patients with FBDS and LGI1
antibodies. We compare those with and without cognitive
impairment, quantify the relative effects of AEDs and im-
munotherapy, address the hypothesis that early immunother-
apy administration may prevent progression to cognitive
impairment (Irani et al., 2011), and explore potential patho-
genic mechanisms of the LGI1 antibodies.
Materials and methods
Standardized questionnaires (Supplementary Table 1) were dis-
tributed to an international network of clinicians who dis-
cussed patients with the Oxford Autoimmune Neurology
Group between 2008 and 2013. Consecutive patients with a
diagnosis of FBDS and serum LGI1 antibodies were included.
Data from 103 patients described clinical and investigation
features, treatment timings and modified Rankin Scale (mRS)
outcomes at 12 (n = 96), 24 (n = 88) and 48 (n = 55) months.
Cognitive impairment was based on the clinical impression,
and was well supported by available cognitive testing
(Supplementary Fig. 1A). Patients and consultees underwent
informed consent (approval REC16/YH/0013).
Statistical analyses were performed in R 3.2.3 and RStudio
Version 0.99.491 (Supplementary material). LGI1-antibody
determination with a novel flow-cytometry assay (FCA) was
developed to quantify serum IgG-subclass deposition on live
HEK293T cells that stably-express membrane-tethered LGI1-
EGFP. ADAM22 co-transfection and soluble LGI1 were used
for internalization experiments (Supplementary material).
Results
Demographics, phenotype and
tumours
Overall, 64 of 103 (62%) patients were male, with a
normal distribution centred on a median age of 64 years,
and a range (22–92 years) that spared children (Fig. 1A).
Only eight (8%) patients had an identified tumour, each a
different type (Supplementary Table 2). Most patients with
FBDS from the UK and USA were Caucasian, and no pa-
tients were of Afro-Caribbean descent (Fig. 1B). In agree-
ment with previous smaller reports (Andrade et al., 2011;
Irani et al., 2011, 2013; Shin et al., 2013; Navarro et al.,
2016; van Sonderen et al., 2016; Aurangzeb et al., 2017),
FBDS showed a high maximal frequency (median 32 per
day, range 2–400), short duration (1–5 s in 74% of pa-
tients) and involvement of arm (99%), face (89%) and
leg (36%) (Supplementary Fig. 1B and C). Examples are
shown in Supplementary Videos 1 and 2.
Differences between patients with
and without cognitive impairment
Compared to patients identified prior to the 2011 description
of FBDS, those identified after 2011 were less likely to have
cognitive impairment [3/46 (7%) versus 19/57 (33%);
P = 0.013, Fisher’s], and received earlier immunotherapy
(median 45 versus 112 days, P = 0.0036, Mann-Whitney U-
test). A comparison of FBDS patients with (n = 81) and with-
out cognitive impairment (n = 22; Supplementary Table 2)
revealed marked similarities in demographics, frequent add-
itional seizure semiologies and other clinical features, except
hallucinations, mood and sleep disturbances, which were
only observed in patients with cognitive impairment.
Medial temporal lobe T2-hyperintensities (mostly involving
the amygdala and hippocampus, P5 0.0001), temporal and
frontal lobe ictal EEG changes (P = 0.0096), and serum hypo-
natraemia (P5 0.0001) were almost only observed in pa-
tients with cognitive impairment (Fig. 1C). Overall, patients
with cognitive impairment had more abnormal investigations
than those with FBDS alone (mean 2.12 versus 0.77,
P5 0.0001, Fig. 1C).
Treatments administered and side
effects
In total, 99 (96%) patients were administered AEDs
(median = 2, range 1–10), most commonly levetiracetam
(n = 69), sodium valproate (n = 37), phenytoin (PHT,
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n = 32), and carbamazepine (CBZ, n = 26). Ninety-eight
(95%) patients received immunotherapy (Supplementary
Table 2): the most common immunotherapy regimes were
corticosteroids alone (n = 36; 37%), corticosteroids plus
intravenous immunoglobulins (IVIG, n = 33; 34%),
corticosteroids plus plasma exchange (PLEX, n = 12;
12%), and all three agents (n = 12; 12%).
Strikingly, cutaneous reactions were seen in a total of 29
(29%) patients on AEDs, including five with Stevens-
Johnson syndrome (Supplementary Fig. 1D). These
Figure 1 Clinical characteristics and investigation findings in 103 patients with faciobrachial dystonic seizures. (A) Age and
gender distribution. The eight patients with known tumours are shown (details in Supplementary Table 2). (B) Ethnicity in patients with FBDS
closely resembled the local population in both UK and USA, except for the absence of Afro-Caribbean cases. (C) Red-coloured boxes highlight
abnormalities in MRI, ictal- and interictal (inter)- EEG (epileptiform features, diffuse and focal slowing), serum sodium, and CSF from patients with
(n = 81) and without (n = 22) cognitive impairment. Sum represents the total number of abnormalities per patient. BG = basal ganglia;
CI = cognitive impairment; Temp = temporal lobe. **P5 0.01, ***P5 0.001, ****P5 0.0001 (Welch’s unequal variance test for the Sum, Fisher’s
exact test used for all others).
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reactions occurred across ethnicities, and were significantly
associated with exposure to CBZ (48% of patients with
cutaneous reactions, P = 0.0099) and to PHT (50%,
P = 0.03; Supplementary Table 3). Side effects of immuno-
therapy were also common, in 43 (44%) patients, and most
frequently affected mood (n = 21) and the musculoskeletal
system (n = 11, myopathy, tendon rupture and osteopor-
osis). Five deaths were attributed to complications from
PLEX [acute respiratory distress syndrome (n = 2), sepsis
(n = 2) and pulmonary emboli (n = 1)].
Cessation of FBDS: a comparison of
antiepileptic drugs and
immunotherapy
Given these high complication rates, the relative efficacies of
AEDs and immunotherapy were investigated (Fig. 2A). Only
9 of 89 (10%) patients initially commenced on AEDs alone
experienced cessation of FBDS, with a wide latency to ces-
sation [median 186 days, interquartile range (IQR) 7–274].
These nine had a lower maximal daily frequency of FBDS
(median 10 versus 40; P = 0.0036, Mann-Whitney U-test),
and no relapses [0/9 (0%) versus 30/94 (32%); P = 0.056,
Fisher’s], perhaps suggesting a milder phenotype. In con-
trast, in the 85 patients with subsequent additional exposure
to immunotherapy, cessation of FBDS was observed in 51%
after 30 days and 88% after 90 days of administration (log-
rank P5 0.0001, Fig. 2A). Furthermore, in the three pa-
tients treated with immunotherapy alone, FBDS stopped
after 2 days (n = 2) and 14 days (n = 1). Overall, this
marked effect of immunotherapy was more pronounced in
the group without cognitive impairment (P = 0.038, Fig.
2B), and post-estimation simulations revealed that for each
day immunotherapy was delayed, there was a 0.69% [95%
confidence interval (CI) 0.32–1.06] relative reduction in the
probability of cessation of FBDS (Fig. 2C). Consistently,
multivariate regression analysis showed that time to cessa-
tion of FBDS was influenced by the number of months to
treatment with immunotherapy [odds ratio (OR) 0.81, 95%
CI 0.72–0.91; P = 0.00024] and the presence of cognitive
impairment (OR 0.53, CI 0.29–0.96; P = 0.035), but not
by time to AED administration, age, sex, or the frequency
of the FBDS (Supplementary Table 4). In summary, whereas
milder cases occasionally responded to AEDs alone, cessa-
tion of FBDS was strikingly enhanced by addition of im-
munotherapy, which appeared similarly efficacious in a
small subset treated with immunotherapy alone.
Factors affecting long-term disability
Persistent cognitive deficits are an established feature of
patients with LGI1-antibody encephalitis (Bettcher et al.,
2014; Butler et al., 2014; Arin˜o et al., 2016; Finke et al.,
2017). Overall, at disease onset, the patients without cog-
nitive impairment showed a lower mRS (P = 0.0032,
Figure 2 The effects of treatments on cessation of facio-
brachial dystonic seizures. (A) Kaplan-Meier survival curve
showing the proportion with FBDS cessation after administration of
AEDs alone (red) and after subsequent additional exposure to im-
munotherapy (blue). (B) Kaplan-Meier survival curve of FBDS ces-
sation after immunotherapy showing more rapid cessation of FBDS
in patients without cognitive impairment. (C) Post-estimation
simulation of the odds ratio of FBDS cessation against the delay to
commencement of immunotherapy after the onset of FBDS. The
standard error and 95% confidence intervals are shown in dark grey
and light grey, respectively. Ticks represent time to starting im-
munotherapy. CI = cognitive impairment; IT = immunotherapy.
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Mann-Whitney U-test), and no cases demonstrated an in-
ability to look after their bodily needs (mRS43,
Supplementary Fig. 1E). Over time, the serial mRS declined
at similar rates in patients with and without cognitive im-
pairment, and poorer mRS outcomes were maintained at 4
years in patients with cognitive impairment (P = 0.0022,
Fig. 3A). Compared with patients who received corticoster-
oids alone, those administered additional immunotherapies
had more severe disease at onset, with similar declines in
mRS (P = 0.0081; Fig. 3B). Ordinal linear regression re-
vealed that the presence of cognitive impairment (OR
6.25, CI 2.09–20.07; P = 0.0014) and, more modestly, the
number of months to immunotherapy (OR 1.16, CI 1.02–
1.34; P = 0.031), but not time to AED administration, pre-
dicted poorer 24-month outcomes (Supplementary Table
4). Taken together, time to cessation of FBDS and longer-
term outcomes were both predicted by the presence of cog-
nitive impairment and by the time to immunotherapy
administration, and additional immunotherapy did not
appear to hasten recovery.
The development of cognitive
impairment with active FBDS
Next, the relative timings of FBDS and cognitive impair-
ment were investigated. In 23 of 103 patients, FBDS were
recognized after onset of cognitive impairment [median of
31 days (IQR 15–90)]. The remaining 80 (78%) patients
experienced FBDS as the presenting clinical feature, and
FBDS resolved with (n = 70) or without (n = 10) immuno-
therapy administration. Twenty-two of 80 never developed
cognitive impairment, with cessation of FBDS after a
median of 103 days (IQR 60–168). Remarkably, of the
remaining 58 who developed cognitive impairment, 57
did so during active FBDS and only one did so after
FBDS cessation (P5 0.0001, Fig. 3C). Furthermore, after
30 and 90 days of ongoing FBDS, 38% and 56% had
developed cognitive impairment (Fig. 3C), respectively, sug-
gesting a narrow therapeutic window within which FBDS
cessation can eliminate the long-term disability associated
with cognitive impairment.
LGI1 antibodies: FCA,
complement-fixing subclasses and
LGI1 internalization
Next, we investigated the effects of LGI1 antibodies in
vitro. The visual cell-based assay showed equivalent sensi-
tivity and specificity to our novel live-cell LGI1-antibody
FCA (Fig. 4A and Supplementary Fig. 2A). However, the
wide dynamic range of the FCA facilitated clinical correl-
ations in the 49 patients with available samples. The FCA
detected higher overall LGI1-IgG levels in patients with
cognitive impairment (P = 0.01, Mann-Whitney U-test,
Fig. 4B). As LGI1-antibody encephalitis brains show com-
plement deposition (Bien et al., 2012), LGI1-IgG subclasses
were assessed. All sera contained non-complement fixing
LGI1-IgG4 antibodies and 28/49 also showed comple-
ment-fixing LGI1-IgG antibodies. Patients with FBDS
alone almost exclusively had LGI1-IgG4 antibodies
(P = 0.009, Mann-Whitney U-test) whereas, overall, pa-
tients with cognitive impairment showed higher propor-
tions of LGI1-IgG1 antibodies (P = 0.03, Mann-Whitney
U-test, Fig. 4C). Furthermore, LGI1-IgG1 antibodies were
undetectable in 7/8 (88%) patients without cognitive im-
pairment versus 14/41 (34%) with cognitive impairment
(P = 0.01, Fisher’s), and greater LGI1-IgG1 proportions
correlated modestly with poorer cognitive scores (P = 0.01
and 0.04, Supplementary Fig. 2B and C). As many of the
patients recovered well with immunotherapy, we explored
a potentially reversible effect of patient LGI1-IgGs in the
presence of a disintegrin and metalloproteinase domain 22
(ADAM22), a known neuronal receptor for LGI1. Soluble
LGI1 was transferred to ADAM22-transfected HEK cells,
Figure 3 Functional outcomes in patients with faciobra-
chial dystonic seizures. (A) Repeat-measure ANOVA (RM-
ANOVA) demonstrated a significant difference in mRS between
patients with (green) and without cognitive impairment (purple).
(B) Repeat-measure ANOVA to compare mRS between patients
treated with steroids and steroids with other immunotherapy (IT) in
combination (broken line), and steroids alone (solid line). (C)
Kaplan-Meier event curve of developing cognitive impairment with
ongoing FBDS (solid line), and after cessation of FBDS (broken line).
CI = cognitive impairment; mRS = modified Rankin Scale.
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Figure 4 LGI1-antibody levels, subclasses and clinical correlations. (A) Flow-cytometry of stably-transfected LGI1-EGFP expressing
cells labelled with IgG from a control patient (grey), and from two patients with FBDS and different LGI1 antibody levels (light blue and dark blue
dot-plot clouds and histograms, median fluorescence intensities represented on both axes). (B) LGI1-IgG levels determined by a novel flow-
cytometry assay (FCA) from 48 available initial samples are higher in patients with cognitive impairment (P = 0.013, Mann-Whitney U-test), error
bars represent standards error of the mean (SEM). (C) LGI1-specific IgG4 antibody and IgG1 antibody levels expressed as a percentage of the
total LGI1-IgG in patients with FBDS or FBDS with cognitive impairment. *P = 0.01; **P = 0.009, both Mann-Whitney U-test. Error bars represent
standard deviations (SD). (D) ADAM22-transfected HEK293T cells incubated with soluble LGI1 followed by sera from patients with FBDS. DAPI
was used to highlight cell nuclei and PKH26 (red) to delineate plasma membranes. Scale bar = 15 mm. Surface bound IgG (at baseline, 0 h) is
internalized after 0.5 h, and more so after 4 h. This was visualized from sera of patients with (n = 3) and without (n = 6) cognitive impairment,
including 6/9 sera with detectable IgG4 LGI1 antibodies only. At 4C the internalization process is inhibited and surface LGI1-IgG remains bound
(control). (E) Quantification of D using flow cytometry with identically treated cells in suspension (****P5 0.0001, n = 3 patients). (F) Schematic
model describing effects of time from FBDS onset on clinical function including cognitive impairment, investigation results and the relative
effects of early and late immunotherapy. The pathogenesis may correspond to a combination of complement deposition and LGI1-ADAM22
complex internalization, amongst other mechanisms (G). ADAM22 = a disintegrin and metalloproteinase domain 22; CI = cognitive impairment;
LGI1-EGFP = leucine-rich, glioma inactivated 1-enhanced green fluorescent fusion protein; HC = healthy control. Experimental details provided in
Supplementary material.
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and incubated IgGs from patient sera were observed to
internalize after 0.5 and 4 h in vitro at 37C, both by visu-
alization (Fig. 4D) and flow-cytometry quantification of
surface IgG (Fig. 4E, P5 0.0001). Internalized LGI1-IgGs
consistently co-localized with ADAM22 (Fig. 4D, inset)
and internalization was observed from the sera of patients
with (n = 3) and without (n = 6) cognitive impairment, and
from LGI1-IgGs with both dominant IgG1 (n = 3) and IgG4
(n = 6) subclasses, but not with healthy control sera (n = 5)
or at 4C, a condition known to inhibit internalization.
Discussion
This study, the largest available series of FBDS, provides a
unique opportunity to describe and quantify the short- and
long-term impacts of delay to treatment in this contempor-
ary syndrome. The description of a substantial cohort with-
out cognitive impairment has demonstrated the importance
of rapid clinical recognition and prompt treatment of FBDS
in the prevention of cognitive impairment. The striking ef-
fects of early immunotherapy relate to cessation of AED-
refractory seizures, and the urgency of accurate diagnosis is
emphasized by a quantifiable daily effect of immunotherapy
delay on seizure cessation. In addition, the rapid develop-
ment of cognitive impairment observed without cessation of
FBDS and the effect of early immunotherapy on long-term
disability, suggest prompt immunotherapy alters the clinical
course of the syndrome. Furthermore, the outcomes of the
groups with and without cognitive impairment did not
appear to converge at 4 years, or with additional immuno-
therapy. This irreversible disability in patients with
cognitive impairment may be secondary to their higher
IgG1-LGI1 antibodies, with subsequent complement depos-
ition and ensuing hippocampal atrophy (Bien et al., 2007,
2012; Arin˜o et al., 2016; Finke et al., 2017). In contrast,
the IgG4-predominant disease of FBDS alone appears lar-
gely reversible and may depend more on the non-inflam-
matory mechanism of LGI1-ADAM22 complex
internalization. In summary, the clinical data presented
allow construction of a model to describe the initiation,
propagation and termination of features associated with
LGI1 antibodies where early immunotherapy-based seizure
cessation is key to optimizing outcomes (Fig. 4F–G).
The modal age distribution of 64 years with male pre-
dominance makes this demographic highly unusual
amongst autoimmune illnesses. The absence of affected
children, Afro-Caribbean patients or consistent tumour
associations, all in striking contrast to patients with
NMDAR-antibodies, suggests potential contributions
from later life environmental triggers and genetic
predispositions, such as the recently described HLA-
DRB1*07:01 association (Kim et al., 2017). As HLA
alleles are associated with AED-related adverse effects,
these may predispose to the observed frequent and often
serious AED hypersensitivities.
The pathognomonic semiology of FBDS and emerging
in vitro data (Ohkawa et al., 2013; Seagar et al., 2017),
suggest LGI1 antibodies are epileptogenic. In these early
stages of the disease, patients with an isolated seizure syn-
drome usually show normal investigations, suggesting a
highly localized disease that is best recognized clinically.
During this period, the FBDS are only minimally responsive
to AEDs but exquisitely responsive to addition of immuno-
therapy, typically corticosteroids. The prominent dystonic
posturing plus the characteristic, but not universal, involve-
ment of the striatum (Irani et al., 2011; Boesebeck et al.,
2013; Flanagan et al., 2015) and motor cortex (Navarro
et al., 2016) in FBDS, suggest restricted cortical-striatal
networks are initially engaged. Consistent with seizure-
prone LGI1- and ADAM22-depleted animals, antibody-
induced internalization of the LGI1-ADAM22 complex
and related proteins may mediate this non-inflammatory
epileptogenesis perhaps via disruption of molecules includ-
ing AMPA receptors and potassium channels (Ohkawa
et al., 2013; Seagar et al., 2017).
Subsequently, patients often developed cognitive impair-
ment accompanied by an increase in both LGI1-IgG levels
and frequency of FBDS (Irani et al., 2011). As this study
utilized clinical observations and several patients did not
have demonstrable inflammation (-itis), cognitive impair-
ment was preferred to the term ‘encephalitis’. This cognitive
impairment became clinically apparent in over half of the
patients after 3 months of active FBDS and correlated well
with medial temporal lobe imaging changes, frontotem-
poral EEG activity and serum hyponatraemia, likely invol-
ving the LGI1-expressing, ADH-secreting hypothalamic
neurons (Irani et al., 2012). Therefore, cognitive impair-
ment appeared closely associated with a transition from
isolated seizures to a widespread cortical and subcortical
disease with increased disability. The FBDS remained
almost universally refractory to AEDs yet remarkably re-
sponsive to immunotherapy with every week of immuno-
therapy delay conferring a 5% relative reduction in the
probability of FBDS cessation.
The remarkably rapid anti-seizure effect of early im-
munotherapy in FBDS, the frequent transition from FBDS
alone to cognitive impairment, low frequency of IgG1-LGI1
antibodies in patients without cognitive impairment, plus
previous preliminary observations (Irani et al., 2011), gen-
erated the hypothesis that cognitive impairment could be
prevented by termination of FBDS. This appeared to be
confirmed in all but one patient, perhaps due to under-re-
ported FBDS, subclinical seizures or a coincident
neurodegenerative condition in this 70-year-old. This
time-dependent intervention, alongside frequent focal seiz-
ures, raises the possibility that this syndrome may be mod-
elled as an adult-onset epileptic encephalopathy, analogous
to limbic status epilepticus (Kaplan et al., 2012). However,
it remains possible that FBDS and cognitive impairment
represent independent manifestations of a common under-
lying pathology.
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Early immunotherapy seems intuitive in patients with
FBDS. However, several apparently intuitive medical inter-
ventions have been proven to be harmful or of no benefit
(Rothwell, 2005). Therefore, moving forwards, our obser-
vations provide evidence in a disease where randomized
trials may never be performed. Although the absence of
prospective data collection, formal neuropsychometry or
video-EEGs limited optimal assessments, they accurately re-
flect and inform neurology practice in this rare condition.
Furthermore, the striking distinctions in investigations sug-
gest the clinical impression of cognitive impairment relates
to biological differences. While this study may not have
captured patients with rapid spontaneous resolution of
FBDS, the rapidity and striking effect-size upon addition
of immunotherapy argue against a delayed effect of
AEDs. Other study limitations include limited data regard-
ing other seizure types, and a generic requirement for meas-
ures more tailored to these patients than the Addenbrooke’s
cognitive examination-revised or mRS.
Despite the sensitivity of FBDS to immunotherapy, and
the successful prevention of ensuing cognitive impairment,
patients with cognitive impairment showed significant re-
sidual disability at 4 years (Bettcher et al., 2014; Butler
et al., 2014; Irani et al., 2014a; Arin˜o et al., 2016; van
Sonderen et al., 2016). These observations suggest that al-
though seizure recognition and termination improve long-
term outcomes, an unmet medical need frequently persists.
Given the observed IgG4-subclass predominance (Arin˜o
et al., 2016) suggests early rituximab may be effective but
has, to date, only been trialled relatively late in the course
of patients with LGI1-antibodies (Irani et al., 2014b).
Funding
S.R.I. and M.M. are supported by the Wellcome Trust
(104079/Z/14/Z), BMA Research Grants - 2013 Vera
Down grant, Epilepsy Research UK (P1201), the Fulbright
UK-US commission and by the National Institute for Health
Research (NIHR) Oxford Biomedical Research Centre
(BRC; The views expressed are those of the author(s) and
not necessarily those of the NHS, the NIHR or the
Department of Health).
Conflicts of interest
P.W., S.R.I., A.V. and B.L. are co-applicants and receive
royalties on patent application WO/2010/046716 entitled
‘Neurological Autoimmune Disorders’. The patent has
been licensed to Euroimmun AG for the development of
assays for LGI1 and other VGKC-complex antibodies. J.G.
declares Genentech; and medicolegal consulting. Research
support to UCSF came from Quest Diagnostics, MedDay
and Genentech. C.G.B. gave scientific advice to Eisai
(Frankfurt, Germany) and UCB (Monheim, Germany),
undertook industry-funded travel with support of Eisai
(Frankfurt, Germany), UCB (Monheim, Germany), Desitin
(Hamburg, Germany), and Grifols (Frankfurt, Germany),
obtained honoraria for speaking engagements from Eisai
(Frankfurt, Germany), UCB (Monheim, Germany), Desitin
(Hamburg, Germany), diamed (Ko¨ln, Germany), Fresenius
Medical Care (Bad Homburg, Germany), Biogen
(Ismaning, Germany) and Euroimmun (Lu¨beck, Germany).
He received research support from diamed (Ko¨ln, Germany)
and Fresenius Medical Care (Bad Homburg, Germany). He
consults for the Laboratory Krone, Bad Salzuflen, Germany.
Supplementary material
Supplementary material is available at Brain online.
Appendix 1
The FBDS study working group: Dr Mu¨jgan Dogan-
Onugoren (Epilepsy Center Bethel, Germany), Dr
Alexander Rae-Grant (Cleveland Clinic, USA), Prof Zsolt
Illes (Department of Neurology, University of Southern
Denmark), Dr Monika Szots (Department of Neurology,
Mor Kaposi General Hospital, Hungary), Drs Michael
Malter, Guido Widman and Rainer Surges (Epilepsy
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